I have a patient who had a failed mesh placement and a panniculectomy and who has developed at least three separate fistulas with a very large amount of output (3-4 L/24 hrs). Any suggestions? I am using an Eakin wound management pouch hooked up to wall suction.
Developing and Evaluating Outcomes of an Evidence-based Protocol for the Treatment of Osteomyelitis in Stage IV Pressure Ulcers
- Wed, 3/25/09 - 11:48am
- 0 Comments
- 11565 reads
Start Page:
42
End Page:
53 Abstract: Osteomyelitis affects up to 32% of full-thickness pressure ulcers and increases treatment costs and the risk of systemic complications. Current diagnosis and treatment practices are variable. A literature and retrospective chart review, using a wound electronic medical record (WEMR), were conducted to develop an evidence-based protocol of care for treatment of osteomyelitis in pressure ulcers and to evaluate outcomes of care. The seven steps in the protocol of care include: 1) acknowledgment of osteomyelitis risk in patients with Stage IV pressure ulcers, 2) clinical evaluation for local or systemic signs of infection upon initial presentation, 3) radiographic evaluation (magnetic resonance imaging or bone scan), 4) surgical debridement to remove all nonviable tissue and/or scarred and infected bone, 5) obtaining pathology reports from sterile bone biopsy and deep microbial cultures, 6) targeted systemic antimicrobial therapy, and 7) tissue reconstruction following resolution of infection. WEMR data review (177 patients) identified 50 patients with osteomyelitis (prevalence 28%). Of those, 41 underwent 87 bone debridements for osteomyelitis. Eight (20%) patients experienced complications related to treatment. Average time to discharge following debridement was 4.3 ± 5.7 days and 76% of wounds with more than two consecutive WEMR entries showed a decrease in area at their final visit. The outcomes observed are encouraging and the WEMR facilitates implementation and evaluation of the treatment protocol. Ongoing data acquisition will help assess outcomes and refine the current management protocol and should improve diagnosis and care.
With 1.3 to 3 million cases diagnosed annually in the US,1 and average charges reaching $37,800,2 pressure ulcers present a serious medical problem for hospitalized and/or bed-bound patients. Pressure ulcers have an estimated prevalence as high as 26% among hospitalized patients,3 53% among nursing home patients,4 and 39% among patients with spinal cord injuries.5 Pressure ulcers are associated with underlying physiologic impairments6-8 and can be difficult to heal even when appropriately treated.
Pressure ulcers increase the length of hospital stay, risk of nosocomial infection, and treatment costs.9 Evidence shows that pressure ulcers are associated with increased mortality rates10 and have been reported as a cause of death in more than 104,000 persons in the US annually.11 Septicemia was an underlying or contributing cause in 39.7% of all pressure ulcer-associated deaths.11
Stage IV pressure ulcers are particularly morbid.
References:
1. Lyder CH. Pressure ulcer prevention and management. JAMA. 2003;289(2):223–226.
2. Hospitalizations related to pressure sores. 2003. Available at: www.hcup–us.ahrq.gov/reports/statbriefs/sb3.pdf. Accessed February 1, 2007.
3. Groeneveld A, Anderson M, Allen S, et al. The prevalence of pressure ulcers in a tertiary care pediatric and adult hospital. J WOCN. 2004;31(3):108–120.
4. Davis CM, Caseby NG. Prevalence and incidence studies of pressure ulcers in two long–term care facilities in Canada. Ostomy Wound Manage. 2001;47(11):28–34.
5. Garber SL, Rintala DH. Pressure ulcers in veterans with spinal cord injury: a retrospective study. J Rehabil Res Dev. 2003;40(5):433–41.
6. Lazarus GS, Cooper DM, Knighton DR, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol. 1994;130(4):489–493.
7. Mostow EN. Diagnosis and classification of chronic wounds. Clin Dermatol. 1994;12(1):3–9.
8. Stojadinovic O, Brem H, Vouthounis C, et al. Molecular pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of epithelialization and wound healing. Am J Pathol. 2005;167(1):59–69.
9. Allman RM, Goode PS, Burst N, Bartolucci AA, Thomas DR. Pressure ulcers, hospital complications, and disease severity: impact on hospital costs and length of stay. Adv Wound Care. 1999;12(1):22–30.
10. Landi F, Onder G, Russo A, Bernabei R. Pressure ulcer and mortality in frail elderly people living in community. Arch Gerontol Geriatr. 2007;44(suppl 1):217–223.
11. Redelings MD, Lee NE, Sorvillo F. Pressure ulcers: more lethal than we thought? Adv Skin Wound Care. 2005;18(7):367–372.
12. Schryvers OI, Stranc MF, Nance PW. Surgical treatment of pressure ulcers: 20–year experience. Arch Phys Med Rehabil. 2000;81(12):1556–1562.
13. Bergstrom N, Braden BJ, Laguzza A, Holman V. The Braden Scale for Predicting Pressure Sore Risk. Nurs Res. 1987;36(4):205–210.
14. Brown G. Long–term outcomes of full–thickness pressure ulcers: healing and mortality. Ostomy Wound Manage. 2003;49(10):42–50.
15. Ford CN, Reinhard ER, Yeh D, et al. Interim analysis of a prospective, randomized trial of vacuum–assisted closure versus the healthpoint system in the management of pressure ulcers. Ann Plast Surg. 2002;49(1):55–61.
16. Han H, Lewis VL, Jr., Wiedrich TA, Patel PK. The value of Jamshidi core needle bone biopsy in predicting postoperative osteomyelitis in grade IV pressure ulcer patients. Plast Reconstr Surg. 2002;110(1):118–122.
17. Thornhill-Joynes M, Gonzales F, Stewart CA, et al. Osteomyelitis associated with pressure ulcers. Arch Phys Med Rehabil. 1986;67(5):314–318.
18. Sugarman B, Hawes S, Musher DM, Klima M, Young EJ, Pircher F. Osteomyelitis beneath pressure sores. Arch Intern Med. 1983;143(4):683–688.
19. Darouiche RO, Landon GC, Klima M, Musher DM, Markowski J. Osteomyelitis associated with pressure sores. Arch Intern Med. 1994;154(7):753–758.
20. Hirshberg J, Rees RS, Marchant B, Dean S. Osteomyelitis related to pressure ulcers: the cost of neglect. Adv Skin Wound Care. 2000;13(1):25–29.
21. Brandeis GH, Morris JN, Nash DJ, Lipsitz LA. The epidemiology and natural history of pressure ulcers in elderly nursing home residents. JAMA. 1990;264(22);2905–2909.
22. Supp DM, Boyce ST. Engineered skin substitutes: practices and potentials. Clin Dermatol. 2005;23(4):403–412.
23. Bonomo SR, Davidson JD, Tyrone JW, Lin X, Mustoe TA. Enhancement of wound healing by hyperbaric oxygen and transforming growth factor beta3 in a new chronic wound model in aged rabbits. Arch Surg. 2000;135(10):1148–1153.
24. Salcido R, Donofrio JC, Fisher SB, et al. Histopathology of pressure ulcers as a result of sequential computer-controlled pressure sessions in a fuzzy rat model. Adv Wound Care. 1994;7(5):23–48.
25. Bouten CV, Breuls RG, Peeters EA, Oomens CW, Baaijens FP. In vitro models to study compressive strain-induced muscle cell damage. Biorheology. 2003;40(1-3):383–388.
26. Breuls RG, Bouten CV, Oomens CW, Bader DL, Baaijens FP. Compression induced cell damage in engineered muscle tissue: an in vitro model to study pressure ulcer aetiology. Ann Biomed Eng. 2003;31(11):1357–1364.
27. Stekelenburg A, Strijkers GJ, Parusel H, Bader D, Nicolay K, Oomens C. The role of ischemia and deformation in the onset of compression–induced deep tissue injury: MRI–based studies in a rat model. J Appl Physiol. 2007;102(5):2002–2011.
28. Brem H, Tomic-Canic M, Tarnovskaya A, et al. Healing of elderly patients with diabetic foot ulcers, venous stasis ulcers, and pressure ulcers. Surg Technol Int. 2003;11:161–167.
29. Brem H, Tomic-Canic M, Entero H, et al. The synergism of age and db/dgenotype impairs wound healing. Exp Gerontol. 2007;42(6):523–531.
30. Barone EJ, Yager DR, Pozez AL, et al. Interleukin–1alpha and collagenase activity are elevated in chronic wounds. Plast Reconstr Surg. 1998;102(4):1023–1027; discussion 1028–10299.
31. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP–2 and MMP-9. J Invest Dermatol. 1993;101(1):64–68.
32. Saarialho–Kere UK. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res. 1998;290(suppl):S47–S54.
33. Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF, Schultz GS. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen. 2002;10(1):26–37.
34. Latijnhouwers MA, Bergers M, Veenhuis RT, Beekman B, Ankersmit-Ter Horst MF, Schalkwijk J. Tenascin-C degradation in chronic wounds is dependent on serine proteinase activity. Arch Dermatol Res 1998;290(9):490–496.
35. Grinnell F, Ho CH, Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J Invest Dermatol. 1992;98(4):410–416.
36. Wallace HJ, Stacey MC. Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers––correlations to healing status. J Invest Dermatol. 1998;110(3):292–296.
37. Tomic-Canic M, Magnus SA, Oscar MA. Epidermal repair and the chronic wound. In: Rovee DT, Maibach HI (eds). The Epidermis in Wound Healing. Florida: CRC Press LLC;2004:25–57.
38. Scott JR, Gibran NS, Engrav LH, Mack CD, Rivara FP. Incidence and characteristics of hospitalized patients with pressure ulcers: State of Washington, 1987 to 2000. Plast Reconstr Surg. 2006;117(2):630–634.
39. van Marum RJ, Meijer JH, Ribbe MW. The relationship between pressure ulcers and skin blood flow response after a local cold provocation. Arch Phys Med Rehabil. 2002;83(1):40–43.
40. Casimiro C, Garc-de-Lorenzo A, Usan L. Prevalence of decubitus ulcer and associated risk factors in an institutionalized Spanish elderly population. Nutrition. 2002;18(5):408–414.
41. Schubert V, Heraud J. The effects of pressure and shear on skin microcirculation in elderly stroke patients lying in supine or semi-recumbent positions. Age Ageing. 1994;23(5):405–410.
42. Bots TC, Apotheker BF. The prevention of heel pressure ulcers using a hydropolymer dressing in surgical patients. J Wound Care. 2004;13(9):375–378.
43. Fisher AR, Wells G, Harrison MB. Factors associated with pressure ulcers in adults in acute care hospitals. Holist Nurs Pract. 2004;18(5):242–253.
44. Theaker C, Mannan M, Ives N, Soni N. Risk factors for pressure sores in the critically ill. Anaesthesia. 2000;55(3):221–224.
45. National Pressure Ulcer Advisory Panel. Pressure ulcer stages revised by NPUAP. Available at: www.npuap.org/pr2.htm. Accessed January 14, 2009.
46. Jackson C. The revised Jackson/Cubbin Pressure Area Risk Calculator. Intensive Crit Care Nurs. 1999;15(3):169–175.
47. Waterlow J. Pressure sores: a risk assessment card. Nurs Times. 1985;81(48):49–55.
48. Norton D. Calculating the risk: reflections on the Norton Scale. Decubitus. 1989;2(3):24–31.
49. Gould D, Goldstone L, Kelly D, Gammon J. Examining the validity of pressure ulcer risk assessment scales: a replication study. Int J Nurs Stud. 2004;41(3):331–339.
50. Jun Seongsook RN, Jeong Ihnsook RN, Lee Younghee RN. Validity of pressure ulcer risk assessment scales; Cubbin and Jackson, Braden, and Douglas scale. Int J Nurs Stud. 2004;41(2):199–204.
51. Galpin JE, Chow AW, Bayer AS, Guze LB. Sepsis associated with decubitus ulcers. Am J Med. 1976;61(3):346–350.
52. Dimant J, Tanael L. Decubitus ulcers: when to suspect osteomyelitis. Geriatrics. 1987;42(6):74–83.
53. Montgomerie JZ, Chan E, Gilmore DS, Canawati HN, Sapico FL. Low mortality among patients with spinal cord injury and bacteremia. Rev Infect Dis. 1991;13(5):867–871.
54. Ruddy MJ, Shen F, Smith JB, Sharma A, Gaffen SL. Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment. J Leukoc Biol. 2004;76(1):135–144.
55. Yu JJ, Ruddy MJ, Wong GC, et al. An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor–dependent signals. Blood. 2007;109(9):3794–3802.
56. Frost HM, Villaneuva AR, Roth H. Pyogenic osteomyelitis: diffusion in live and dead bone with particular reference to the tetracycline antibiotics. Henry Ford Hosp Med Bull. 1960;8:255–262.
57. Fong IW, Rittenhouse BR, Simbul M, Vandenbroucke AC. Bone penetration of enoxacin in patients with and without osteomyelitis. Antimicrob Agents Chemother. 1988;32(6(:834–837.
58. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother. 1988;32(9):1320–1322.
59. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115–137.
60. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332(5):305–311.
61. Klosterhalfen B, Peters KM, Tons C, Hauptmann S, Klein CL, Kirkpatrick CJ. Local and systemic inflammatory mediator release in patients with acute and chronic posttraumatic osteomyelitis. J Trauma. 1996;40(3):372–378.
62. Livesley N, Chow A. Infected pressure ulcers in elderly individuals. Clin Infect Dis. 2002:35(11):1390–1396.
63. Cohen MD, Cory DA, Kleiman M, Smith JA, Broderick NJ. Magnetic resonance differentiation of acute and chronic osteomyelitis in children. Clin Radiol. 1990;41(1):53–56.
64. Gilbert DN, Tice AD, Marsh PK, Craven PC, Preheim LC. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram–negative bacilli. Am J Med. 1987;82(4A):254–258.
65. Weiland AJ, Moore JR, Daniel RK. The efficacy of free tissue transfer in the treatment of osteomyelitis. J Bone Joint Surg Am 1984;66(2):181–193.
66. May JW, Jr., Jupiter JB, Weiland AJ, Byrd HS. Clinical classification of post–traumatic tibial osteomyelitis. J Bone Joint Surg Am. 1989;71(9):1422–1428.
67. Bachur R, Pagon Z. Success of short-course parenteral antibiotic therapy for acute osteomyelitis of childhood. Clin Pediatr. (Phila) 2007;46(1):30–35.
68. Lu WJ, Li B, Bao NR, et al. Treatment of chronic osteomyelitis with one–stage allograft. Chin J Traumatol. 2006;9(5):272–275.
69. Cunha BA. Osteomyelitis in elderly patients. Clin Infect Dis. 2002;35(3):287–293.
70. Lewis VL Jr, Bailey MH, Pulawski G, Kind G, Bashioum RW, Hendrix RW. The diagnosis of osteomyelitis in patients with pressure sores. Plast Reconstr Surg. 1988;81(2):229–232.
71. Brem H, Lyder C. Protocol for the successful treatment of pressure ulcers. Am J Surg. 2004;188(1A suppl):9–17.
72. Wrobel JS, Connolly JE. Making the diagnosis of osteomyelitis. The role of prevalence. J Am Podiatr Med Assoc. 1998;88(7):337–343.
73. Brem H, Sheehan P, Rosenberg HJ, Schneider JS, Boulton AJ. Evidence-based protocol for diabetic foot ulcers. Plast Reconstr Surg. 2006;117:193(7 suppl):193S–209S; discussion 210S–211S.
74. Unkila–Kallio L, Kallio MJ, Eskola J, Peltola H. Serum C–reactive protein, erythrocyte sedimentation rate, and white blood cell count in acute hematogenous osteomyelitis of children. Pediatrics. 1994;93(1):59–62.
75. Floyed RL, Steele RW. Culture–negative osteomyelitis. Pediatr Infect Dis J. 2003;22(8):731–736.
76. Howard CB, Einhorn M, Dagan R, Yagupski P, Porat S. Fine-needle bone biopsy to diagnose osteomyelitis. J Bone Joint Surg Br. 1994;76(2):311–314.
77. Scivoletto G, Fuoco U, Morganti B, Cosentino E, Molinari M. Pressure sores and blood and serum dysmetabolism in spinal cord injury patients. Spinal Cord. 2004;42(8):473–476.
78. Buckland-Wright JC, Lynch JA, Dave B. Early radiographic features in patients with anterior cruciate ligament rupture. Ann Rheum Dis. 2000;59(8):641–646.
79. Tumeh SS, Aliabadi P, Weissman BN, McNeil BJ. Disease activity in osteomyelitis: role of radiography. Radiology. 1987;165(3):781–784.
80. Haas ML, Kennedy AS, Copeland CC, Ames JW, Scarboro M, Slawson RG. Utility of radiation in the prevention of heterotopic ossification following repair of traumatic acetabular fracture. Int J Radiat Oncol Biol Phys. 1999;45(2):461–466.
81. Kaim AH, Gross T, von Schulthess GK. Imaging of chronic posttraumatic osteomyelitis. Eur Radiol. 2002;12(5):1193–1202.
82. Wing VW, Jeffrey RB Jr, Federle MP, Helms CA, Trafton P. Chronic osteomyelitis examined by CT. Radiology. 1985;154(1):171–174.
83. Kapoor A, Page S, Lavalley M, Gale DR, Felson DT. Magnetic resonance imaging for diagnosing foot osteomyelitis: a meta-analysis. Arch Intern Med. 2007;167(2):125–132.
84. Azouz EM. Computed tomography in bone and joint infections. J Can Assoc Radiol. 1981;32(2):102–106.
85. Santiago Restrepo C, Gimenez CR, McCarthy K. Imaging of osteomyelitis and musculoskeletal soft tissue infections: current concepts. Rheum Dis Clin North Am. 2003;29(1):89–109.
86. Ma LD, Frassica FJ, Bluemke DA, Fishman EK. CT and MRI evaluation of musculoskeletal infection. Crit Rev Diagn Imaging. 1997;38(6):535–568.
87. Deely DM, Schweitzer ME. MR imaging of bone marrow disorders. Radiol Clin North Am. 1997;35(1):193–212.
88. Morrison WB, Schweitzer ME, Wapner KL, Hecht PJ, Gannon FH, Behm WR. Osteomyelitis in feet of diabetics: clinical accuracy, surgical utility, and cost-effectiveness of MR imaging. Radiology. 1995;1969(2):557–564.
89. Morrison WB, Schweitzer ME, Batte WG, Radack DP, Russel KM. Osteomyelitis of the foot: relative importance of primary and secondary MR imaging signs. Radiology. 1998;207(3):625–632.
90. Davies AM, Hughes DE, Grimer RJ. Intramedullary and extramedullary fat globules on magnetic resonance imaging as a diagnostic sign for osteomyelitis. Eur Radiol. 2005;15(10):2194–2199.
91. Huang AB, Schweitzer ME, Hume E, Batte WG. Osteomyelitis of the pelvis/hips in paralyzed patients: accuracy and clinical utility of MRI. J Comput Assist Tomogr. 1998;22(3):437–443.
92. Melkun ET, Lewis VL, Jr. Evaluation of (111) indium–labeled autologous leukocyte scintigraphy for the diagnosis of chronic osteomyelitis in patients with grade IV pressure ulcers, as compared with a standard diagnostic protocol. Ann Plast Surg. 2005;54(6):633–636.
93. Whitney J, Phillips L, Aslam R, et al. Guidelines for the treatment of pressure ulcers. Wound Repair Regen. 2006;14(6):663–679.
94. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother. 1990;34(1):40–43.
95. Eckardt JJ, Wirganowicz PZ, Mar T. An aggressive surgical approach to the management of chronic osteomyelitis. Clin Orthop Relat Res. 1994;298:229–239.
96. Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother. 2000;44(1):164–166.
97. Mathes SJ, Alpert BS, Chang N. Use of the muscle flap in chronic osteomyelitis: experimental and clinical correlation. Plast Reconstr Surg. 1982;69(5):815–829.
98. Clawson DK, Dunn AW. Management of common bacterial infections of bones and joints. J Bone Joint Surg Am. 1967;49(1):164–182.
99. Deloach ED, DiBenedetto RJ, Womble L, Gilley JD. The treatment of osteomyelitis underlying pressure ulcers. Decubitus. 1992;5(6):32–41.
100.Damjanov I, Linder J, Anderson WAD. Anderson's Pathology, 10th ed. St. Louis. MO: Mosby;1996:416–447.
101.Sugarman B. Pressure sores and underlying bone infection. Arch Intern Med. 1987;14793):553–555.
102.Khatri G, Wagner DK, Sohnle PG. Effect of bone biopsy in guiding antimicrobial therapy for osteomyelitis complicating open wounds. Am J Med Sci. 2001;321(6):367–371.
103. Dubey L, Krasinski K, Hernanz–Schulman M. Osteomyelitis secondary to trauma or infected contiguous soft tissue. Pediatr Infect Dis J. 1988;7(1):26–34.
104. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection. 2004;32(1):8–14.
105. Bernard L, Vaudaux P, Vuagnat A, et al. Effect of vancomycin therapy for osteomyelitis on colonization by methicillin-resistant Staphylococcus aureus: lack of emergence of glycopeptide resistance. Infect Control Hosp Epidemiol. 2003;24(9):650–654.
106. Rajaduraipandi K, Mani KR, Panneerselvam K, Mani M, Bhaskar M, Manikandan P. Prevalence and antimicrobial susceptibility pattern of methicillin–resistant Staphylococcus aureus: a multicentre study. Indian J Med Microbiol. 2006;24(1):34–38.
107. Fowler VG, Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–665.
108. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended–infusion dosing strategy. Clin Infect Dis. 2007;44(3):357–363.
109. Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. Systematic review and meta–analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis. 2001;1(3):175–188.
110. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy. Int J Antimicrob Agents. 2004;23(3):240–246.
111. Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin. Antimicrob Agents Chemother. 1993;37(8):1649–1654.
112. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded multicentre trial. Lancet. 2005;366(9498):1695–1703.
113. Isaac MR, Kanat IO. Bone grafts in the management of osteomyelitis. J Foot Surg. 1986;25(5):404–406.
114. Archdeacon MT, Messerschmitt P. Modern Papineau technique with vacuum-assisted closure. J Orthop Trauma. 2006;20(2):134–137.
115. Monsivais JJ. Effective management of osteomyelitis after grade III open fractures. J South Orthop Assoc. 1996;5(1):30–36.
116. Tulner SA, Schaap GR, Strackee SD, Besselaar PP, Luitse JS, Marti RK. Long–term results of multiple-stage treatment for posttraumatic osteomyelitis of the tibia. J Trauma. 2004;56(3):633–642.
117. Mathes SJ, Feng LJ, Hunt TK. Coverage of the infected wound. Ann Surg. 1983;198(4):420–429.
118. Bruck JC, Bittemeyer R, Grabosch A, Gruhl L. More arguments in favor of myocutaneous flaps for the treatment of pelvic pressure sores. Ann Plast Surg. 1991;26(1):85–88.
119. Foster RD, Anthony JP, Mathes SJ, Hoffman WY. Ischial pressure sore coverage: a rationale for flap selection. Br J Plast Surg. 1997;50(5):374–379.
120. Wong TC, Ip FK. Comparison of gluteal fasciocutaneous rotational flaps and myocutaneous flaps for the treatment of sacral sores. Int Orthop. 2006;30(1):64–67.
121. Lee KS, Han SB, Baek JR. Free vascularized osteocutaneous fibular graft to the tibia in 51 consecutive cases. J Reconstr Microsurg. 2004;20(4):277–284.
122. Lee KS, Park JW. Free vascularized osteocutaneous fibular graft to the tibia. Microsurgery. 1999;19(3):141–147.
123. Ohtani T, Mizuashi M, Ito Y, Aiba S. Cadexomer as well as cadexomer iodine induces the production of proinflammatory cytokines and vascular endothelial growth factor by human macrophages. Exp Dermatol. 2007;16(4):318–323.
124. Lamme EN, Gustafsson TO, Middelkoop E. Cadexomer-iodine ointment shows stimulation of epidermal regeneration in experimental full-thickness wounds. Arch Dermatol Res. 1998;290(1-2):18–24.
125. Zhou LH, Nahm WK, Badiavas E, Yufit T, Falanga V. Slow release iodine preparation and wound healing: in vitro effects consistent with lack of in vivo toxicity in human chronic wounds. Br J Dermatol. 2002;146(3):365–374.
126. Boxer AM, Gottesman N, Bernstein H, Mandl I. Debridement of dermal ulcers and decubiti with collagenase. Geriatrics. 1969;24(7):75–86.
127. Rao DB, Sane PG, Georgiev EL. Collagenase in the treatment of dermal and decubitus ulcers. J Am Geriatr Soc. 1975;23(1):22–30.
128. Kucan JO, Robson MC, Heggers JP, Ko F. Comparison of silver sulfadiazine, povidone-iodine and physiologic saline in the treatment of chronic pressure ulcers. J Am Geriatr Soc. 1981;29(5):232–235.
129. Landi F, Aloe L, Russo A, et al. Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial. Ann Intern Med. 2003;139(8):635–641.
130. Payne WG, Ochs DE, Meltzer DD, et al. Long-term outcome study of growth factor–treated pressure ulcers. Am J Surg. 2001;181(1):81–86.
131. Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen. 1999;7(3):141–147.
132. Muangman P, Engrav LH, Heimbach DM, et al. Complex wound management utilizing an artificial dermal matrix. Ann Plast Surg. 2006;57(2):199–202.
133. Brem H, Balledux J, Bloom T, Kerstein MD, Hollier L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg. 2000;135(6):627–634.
134. Komaki H, Tanaka T, Chazono M, Kikuchi T. Repair of segmental bone defects in rabbit tibiae using a complex of beta–tricalcium phosphate, type I collagen, and fibroblast growth factor–2. Biomaterials. 2006;27(29):5118–5126.
135. Hosseinkhani H, Hosseinkhani M, Tian F, Kobayashi H, Tabata Y. Bone regeneration on a collagen sponge self-assembled peptide-amphiphile nanofiber hybrid scaffold. Tissue Eng. 2007;13(1):11–19.
136. Yamamoto M, Takahashi Y, Tabata Y. Enhanced bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein–2 from a biodegradable hydrogel. Tissue Eng. 2006;12(5):1305–1311.
137. Guizzardi S, Martini D, Bacchelli B, et al. Effects of heat deproteinate bone and polynucleotides on bone regeneration: an experimental study on rat. Micron. 2007;38(7):722–728.
138. Itaka K, Ohba S, Miyata K, et al. Bone regeneration by regulated in vivo gene transfer using biocompatible polyplex nanomicelles. Mol Ther. 2007;15(9):1655–1662.
139. Courtney BA, Ruppman JB, Cooper HM. Save our skin: initiative cuts pressure ulcer incidence in half. Nurs Manage. 2006;37(4):36–40.
140. Hampton S, Collins F. Reducing pressure ulcer incidence in a long-term setting. Br J Nurs. 2005;14(15 suppl):S6–S12.
141. Klay M, Marfyak K. Use of a continence nurse specialist in an extended care facility. Urol Nurs. 2005;25(2):101–108.
Post new comment